Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9941608 | 0.88 | CYP19A1 (0.70) | MAPTKMT2ACYP19A1TSHRMEN1 | |
| SCHEMBL28498335 | 0.88 | CA1 (0.60) | MAPTKMT2ASMN1; SMN2POLBHSD17B10 | |
| SCHEMBL13063891 | 0.83 | KMT2A (0.71) | MAPTKMT2APOLBTSHRHSD17B10 | |
| SCHEMBL12793678 | 0.83 | KMT2A (0.75) | MAPTKMT2APOLBTSHRHSD17B10 | |
| SCHEMBL19392334 | 0.83 | KMT2A (0.75) | MAPTKMT2ASMN1; SMN2POLBTSHR | |
| SCHEMBL15609263 | 0.83 | KMT2A (0.71) | MAPTKMT2APOLBTSHRHSD17B10 | |
| SCHEMBL9941503 | 0.83 | KMT2A (0.70) | MAPTKMT2ASMN1; SMN2POLBTSHR | |
| SCHEMBL1040562 | 0.83 | MAPT (0.76) | MAPTKMT2ASMN1; SMN2POLBMEN1 | |
| SCHEMBL9941834 | 0.82 | KMT2A (0.57) | MAPTKMT2APOLBTSHRHSD17B10 | |
| SCHEMBL31681308 | 0.81 | KMT2A (0.68) | MAPTKMT2ASMN1; SMN2POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140088187-A1 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088187-A1 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088187-A1 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2014-03-27 | — | — | US | disclosed |
| EP-2651412-A2 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | Beth Israel Deaconess Medical Center (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012082862-A2 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088187-A1 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | AR, NR5A1, ESRRB | MAPT 4552/4885KMT2A 1368/4885CYP19A1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.